Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. Founded in 1963, AEPC is the world's largest association in congenital cardiology, uniting over 1,000 specialists from 32 European countries and beyond. This year's meeting, hosted by the University of Padova, features a scientific program centered on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is driving clinical progress.
Ventripoint will exhibit alongside its European distributor, AngioPro, focusing on the power of tracking cardiac function over time in congenital heart disease (CHD) patients using VMS+™. The importance of this approach is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for longitudinal assessment of ventricular function.
Ventripoint's priority for 2026 is accelerating integration of VMS+™ into routine clinical practice. The latest release, VMS+™ 4.0, streamlines workflows, reduces assessment time, and makes advanced cardiac analysis accessible at the point of care. At a patient's first echocardiogram, VMS+™ provides accurate volumetric cardiac measurements equivalent to MRI, supporting clinical decision-making across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint is an industry leader in applying artificial intelligence to echocardiography. Its VMS+™ product family is powered by proprietary KBR technology and delivers volumetric cardiac measurements with accuracy equivalent to MRI. VMS+™ is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada.
